ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

GRFS Grifols SA

6.56
-0.09 (-1.35%)
Apr 12 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 938,741
Bid Price 6.50
Ask Price 6.77
News -
Company Name Stock Ticker Symbol Market Type
Grifols SA GRFS NASDAQ Depository Receipt
  Price Change Change Percent Stock Price Last Traded
-0.09 -1.35% 6.56 17:16:11
Open Price Low Price High Price Close Price Prev Close
6.57 6.49 6.63 6.56 6.65
Trades Volume VWAP Dollar Volume Avg Volume
7,871 938,741  6.54  6,143,760 -
Last Trade Time Type Quantity Stock Price Currency
16:01:36 priorref 412  6.56 USD

Grifols SA Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
3.61B 426.13M - 6.59B 59.32M 0.14 60.78
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

News Grifols

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No GRFS Message Board. Create One! See More Posts on GRFS Message Board See More Message Board Posts

GRFS Historical

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.00%
1 Month0.000.000.000.0000.000.00%
3 Months0.000.000.000.0000.000.00%
6 Months0.000.000.000.0000.000.00%
1 Year0.000.000.000.0000.000.00%
3 Years0.000.000.000.0000.000.00%
5 Years0.000.000.000.0000.000.00%

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. A leader in essential plasma-derived medicines and transfusion medicine we develop produce and provide innovative healthcare services and solutions in more than 110 countries. Patient needs and our ever-growing knowledge of many chronic rare and prevalent diseases sometimes life-threatening drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology hepatology and intensive care pulmonology hematology neurology and infectious diseases. With a workforce of over 27000 employees in more than 30 countries and regions we are committed to a sustainable business model that sets the standard for continuous innovation quality safety and ethical leadership in the industry.

Your Recent History

Delayed Upgrade Clock